Form 4: Coherus CFO McMichael Granted Equity Awards

Coherus Oncology's Chief Financial Officer, Bryan J. McMichael, was granted 112,500 restricted stock units and options to purchase 225,000 shares of common stock.

Summary

• Bryan J. McMichael, Chief Financial Officer of Coherus Oncology, Inc. (CHRS), was granted equity awards on January 22, 2026.
• The grants include 112,500 Restricted Stock Units (RSUs) at a price of $0 per unit, which entitle him to receive one share of Common Stock per RSU upon vesting.
• The RSUs will vest in two tranches: 50% on May 20, 2027, and the remaining 50% on March 20, 2029, contingent on his continued service.
• Additionally, Mr. McMichael received options to purchase 225,000 shares of Common Stock with an exercise price of $1.59 per share.
• These stock options will vest as to 1/4th of the total shares on January 22, 2027, and then in successive, equal monthly installments of 1/48th of the total shares thereafter, also subject to his continued service.
• The stock options have an expiration date of January 22, 2036.
• Following these transactions, Mr. McMichael beneficially owns 133,736 shares of Common Stock (including the newly granted RSUs) and 225,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is generally viewed positively as it aligns management's long-term interests with those of shareholders, incentivizing performance and retention. This is a routine compensation event rather than a direct operational or financial performance indicator.

Positives

• The grant of equity awards aligns the Chief Financial Officer's long-term financial interests with those of Coherus Oncology shareholders, incentivizing sustained performance.
• Equity compensation packages are a standard mechanism for executive retention, helping to secure key management talent.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon Bryan J. McMichael's continued service relationship with Coherus Oncology, Inc.
• The ultimate value realized from these equity awards is subject to the future market performance of Coherus Oncology's common stock.

Future Outlook

The equity grants are designed to incentivize the Chief Financial Officer's long-term performance and retention, with vesting schedules extending through March 2029 for RSUs and options exercisable until January 2036, aligning future executive efforts with shareholder value creation.

Industry Context

Equity compensation, including restricted stock units and stock options, is a common practice in the biotechnology and pharmaceutical industry to attract, retain, and motivate key executives. This filing reflects a standard approach to executive incentive compensation within the sector.

Comparison to Industry Standards

• The structure of equity grants, combining RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation packages observed across the biotechnology and pharmaceutical industry.
• The use of Rule 10b5-1(c) plans for equity transactions is a standard corporate governance practice to provide an affirmative defense against insider trading allegations, common among publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants are designed to align the Chief Financial Officer's incentives with shareholder value creation, potentially leading to improved long-term company performance.
• Employees: The compensation structure for key executives can influence overall company morale and compensation strategies.

Next Steps

• Bryan J. McMichael's continued service with Coherus Oncology, Inc. is required for the vesting of the granted Restricted Stock Units and stock options.
• The stock options may be exercised by Mr. McMichael at the specified exercise price once they vest and before their expiration date.

Key Dates

Keywords

Coherus Oncology, CHRS, Form 4, insider transaction, equity grant, restricted stock units, RSU, stock options, executive compensation, Bryan J. McMichael